Swedish Orphan Biovitrum AB's (publ) (Sobi) partner Biogen Idec today, at the Credit Suisse Global Healthcare Conference in Phoenix, stated that the US Food and Drug Administration (FDA) has requested additional information pertaining to process validation of certain steps in the manufacturing process for ELOCTATE. As a result, Biogen Idec expects a PDUFA extension for ELOCTATE and the company is now planning for a mid-2014 commercial launch in the US based on on-going discussions with the FDA. Sobi believes that this updated timeline for FDA approval is unlikely to impact planned European approval timelines. - - - About the Fc Fusion Technology Platform ELOCTATE is a clotting factor under development using Biogen Idec's novel and proprietary monomeric Fc fusion technology, which makes use of a naturally occurring pathway that delays the breakdown of factor in the body and cycles it back into the bloodstream, resulting in a longer circulating half-life. Fc fusion technology is used in seven FDA-approved products for the treatment of chronic diseases including rheumatoid arthritis, psoriasis and platelet disorders. Biogen Idec is the first and only to apply this proprietary technology to haemophilia. About Haemophilia A Haemophilia A is a rare, inherited disorder in which the ability of a person's blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male births annually and is caused by having substantially reduced or no factor VIII activity, which is needed for normal blood clotting. People with haemophilia A experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhage. Injections of factor VIII can restore the coagulation process, control bleeding, and prevent new bleeding episodes. The Medical and Scientific Advisory Council of the National Haemophilia Foundation recommends prophylaxis as the optimal therapy for people with severe haemophilia A. Currently, prophylaxis in haemophilia A typically requires injections three times per week or every other day to maintain a sufficient circulating level of clotting factor. About the Biogen Idec and Sobi Collaboration Biogen Idec and Swedish Orphan Biovitrum (Sobi) are partners in the development and commercialization of ELOCTATE in haemophilia A and ALPROLIX in haemophilia B. Biogen Idec leads development, has manufacturing rights, and has commercialization rights in North America and all other regions excluding the Sobi territory. Sobi has the right to opt in to assume final development and commercialization in Europe (including Russia), the Middle East and Northern Africa. About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. About Biogen Idec Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, haemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $5 billion in annual revenues. For product labelling, press releases and additional information about the company, please visit www.biogenidec.com. For more information - not for publication Sobi: Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 E: oskar.bosson@sobi.com E: jorgen.winroth@sobi.com [HUG#1742595]
Sobi's partner Biogen Idec expects mid-2014 US launch of
Top 10 Most Recent News Articles
Hyliion Class Action Deadline Nears for Investors
Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...
Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil
Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...
Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang
They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...
Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest
A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...
Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower
Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....
Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors
Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...
Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring
Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...
Continue ReadingTop 5 Most Recently Viewed Articles
C3.ai Investors Urged to Join Class Action for Loss Recovery
C3.ai Investors Should Take Action Investors in C3.ai, Inc. who have experienced losses should consider contacting Levi & Korsinsky, LLP regarding a significant class action lawsuit involving the company. As the situation unfolds, it's crucial for affected shareholders to stay informed and know their rights. Class Action Lawsuit Overview The class action lawsuit targets...
Continue Reading
Chime Celebrates Major Milestone with Over $30 Billion in Transactions
Chime hit a remarkable milestone with its SpotMe feature, reaching over $30 billion in transactions since launch. This fee-free overdraft service is a game changer for consumers tired of getting walloped by $35 fees at traditional banks every time they overdraw their accounts. You know how it goes: people are often only going into the red by less than $26, yet banks...
Continue Reading
Important Legal Update for Warner Bros. Discovery, Inc. Investors
Legal Update for Warner Bros. Discovery, Inc. (NASDAQ: WBD) Investors Warner Bros. Discovery, Inc. (NASDAQ: WBD) is making headlines with an important legal notification for its investors. Bernstein Liebhard LLP, a law firm known for advocating on behalf of investors, has issued an alert regarding a significant deadline associated with a securities fraud class action...
Continue Reading
HealthSherpa Unveils Innovative Policy Status API for ICHRA
HealthSherpa's Groundbreaking Policy Status API The latest API provides unprecedented insights into ACA policy status for ICHRA platforms, enhancing compliance and enabling growth. HealthSherpa, a pioneer in the ICHRA space, has officially introduced its Policy Status API, unique in its ability to monitor individual ACA policy statuses effectively. As the trend of...
Continue Reading
Beyond Meat Partners with Hard Rock Cafe for Burger Launch
Beyond Meat and Hard Rock Cafe Collaboration Beyond Meat, Inc. (NASDAQ: BYND), an innovator in plant-based proteins, is excited to announce a partnership with Hard Rock Cafe, introducing the newest Beyond Burger across all its North American locations. This initiative allows diners to swap any beef burger from Hard Rock's core and kids' menus for the delicious and...
Continue Reading